S1 Table. Treatment characteristics of LACC patients

| Type of treatment          | Cisplatin<sup>a</sup> (n=126) | Gemcitabine<sup>b</sup> (n=63) | p-value |
|----------------------------|---------------------------------|-------------------------------|---------|
| **No. of CT cycles received** |                                 |                               |         |
| 3 cycles                   | 8 (6.3)                         | 5 (7.9)                       |         |
| 4 cycles                   | 31 (24.6)                       | 20 (31.7)                     | 0.159<sup>c</sup> |
| 5 cycles                   | 48 (38.1)                       | 24 (38.1)                     |         |
| 6 cycles                   | 38 (30.2)                       | 14 (22.2)                     |         |
| 7 cycles                   | 1 (0.8)                         | 0 (0)                         |         |
| **RT dosage (Gy)**         | 78.7±5.9                        | 79.6±5.3                      | 0.526<sup>d</sup> |
| **Protraction time (day)** | 75.4±22.1                       | 76.8±21.2                     | 0.384<sup>d</sup> |
| **Brachytherapy**          |                                 |                               |         |
| High rate                  | 67 (53.2)                       | 35 (55.6)                     | 0.757<sup>c</sup> |
| Low rate                   | 59 (46.8)                       | 28 (44.4)                     |         |

Values are presented as number (%) or mean±SD. CT, chemotherapy; LACC, locally advanced cervical cancer; RT, radiotherapy; SD, standard deviation. <sup>a</sup>Cisplatin dose was 40 mg/m<sup>2</sup>, <sup>b</sup>Gemcitabine dose was 300 mg/m<sup>2</sup>, <sup>c</sup>Chi-square test, <sup>d</sup>Student T test for independent samples.